Calcitonin Gene-Related Peptide

The FDA has approved expanding the indication of Qulipta, an oral calcitonin gene-related peptide receptor antagonist, for preventing migraine in adults.

The cause of midlife migraines in women is likely multifactorial, though research suggests that fluctuating hormone levels may play a role, according to a speaker at the North American Menopause Society annual meeting.

Women with menstrual migraine who were treated with galcanezumab had fewer monthly migraine headache days compared with women who received placebo, according to an analysis of three phase 3 trials.

Patients with migraine who took calcitonin gene-related peptide-targeted monoclonal antibody therapy in combination with onabotulinumtoxinA had fewer monthly headache days and less migraine-related disability, according to researchers.

In the phase 3 MOMENTUM and INTERCEPT trials, the investigational migraine drug AXS-07 met its coprimary endpoints of pain freedom and freedom from most bothersome symptom at 2 hours compared with placebo.

Calcitonin gene-related peptide, or CGRP, monoclonal antibodies reduced headache frequency among a small cohort of older adults with migraine, data show.

A host of new migraine-specific therapies were reviewed during this year’s American Headache Society Annual Scientific Meeting. The treatments that are receiving the most attention are those that target calcitonin gene-related peptide.

Treating patients who have chronic migraine with both onabotulinumtoxinA and calcitonin gene-related peptide monoclonal antibody medications could reduce their monthly migraine days by an additional 5.6 days than if they had just received onabotulinumtoxinA alone, according to research presented at the American Headache Society Annual Meeting.

PHILADELPHIA — The oral calcitonin gene-related peptide antagonist ubrogepant provided better pain relief than triptans in patients with migraine, according to study results presented at the American Headache Society Annual Scientific Meeting.